9966.HK - Alphamab Oncology

HKSE - HKSE Delayed Price. Currency in HKD

7.610

+0.100

(+1.33%)

At close: 04:08PM HKT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	7.510
Open	7.570
Bid	7.610 x N/A
Ask	7.660 x N/A
Day's Range	7.430 - 7.830
52 Week Range	5.450 - 17.700
Volume	5,997,982
Avg. Volume	7,388,672

Market Cap	7.342B
Beta (5Y Monthly)	0.61
PE Ratio (TTM)	N/A
EPS (TTM)	-0.360
Earnings Date	Mar 31, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	15.89

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 9966.HK

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

PR Newswire
Alphamab Oncology updated clinical research data for KN026 in Combination with KN046 in HER2-Positive Solid Tumors at the ASCO 2023 annual meeting
Alphamab Oncology (stock code: 9966.HK) announced that updated data from the phase II clinical study of the chemo-free regimen of KN026 in combination with KN046 (KN026-203) were presented at the 2023 American Society of Clinical Oncology (2023 ASCO) Annual Meeting. The e-poster can be accessed on the company's website at www.alphamabonc.com.
PR Newswire
IND Application for Phase Ⅲ Registration Study of KN026 in Combination with Chemotherapy for the First-line Treatment of Breast Cancer Was Approved by CDE
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. jointly announced that the IND application was approved in China for the pivotal trial of the anti-HER2 bispecific antibody KN026 combined with Docetaxel (albumin-binding), in the first-line HER2 positive recurrent metastatic breast cancer.
PR Newswire
Late-Breaking Research - Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023
Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) were presented as a poster at the Late-Breaking Research session of the AACR Annual Meeting 2023 (AACR 2023).
PR Newswire
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed with 2.1mg/kg in a Phase I clinical study (JSKN003-102) of JSKN003, an Anti-HER2 bispecific ADC.
PR Newswire
Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023
Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) is accepted as Late-Breaking Research in 114th Annual Meeting of the American Association for Cancer Research (AACR 2023). The results will be presented as poster(Abstract: LB021).
PR Newswire
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer at SABCS 2022
Alphamab Oncology (stock code: 9966.HK) announced that data from phase II clinical study (clinical trial No.: KN026-208) of HER2 bispecific antibody KN026 in combination with docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer as a Poster at the San Antonio Breast Cancer Symposium (SABCS 2022).
PR Newswire
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer at SABCS 2022
Alphamab Oncology (stock code: 9966.HK) announced that data from phase II clinical study (clinical trial No.: KN026-201) of HER2 bispecific antibody KN026 in combination with Docetaxel for the treatment of patients with HER2-positive recurrent/metastatic breast cancer presented as a Spotlight Poster at the San Antonio Breast Cancer Symposium (SABCS 2022).
PR Newswire
Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022
Alphamab Oncology (stock code: 9966.HK) announced that data from phase Ib/II clinical study (clinical trial No.: KN046-203) of PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) presented was selelcted as spotlight poster presentation at the 45th San Antonio Breast Cancer Symposium (SABCS 2022).
PR Newswire
Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology
Alphamab Oncology (stock code: 9966.HK) announced that results from three clinical studies of KN026 (anti-HER2 bispecific antibody) and KN046 (PD-L1/CTLA4 bispecific antibody) will be presented as Spotlight Poster Discussion or Poster Presentation at the 45th San Antonio Breast Cancer Symposium (SABCS 2022) from 6-10 December 2022.
PR Newswire
Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022
Alphamab Oncology (stock code: 9966.HK) announced that data from the phase II study of KN046 in patients with metastatic non-small cell lung cancer (NSCLC) who failed first line treatment or prior EGFR-TKIs were presented as a Poster at the ESMO Congress 2022 (ESMO 2022).
PR Newswire
Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line（1L）treatment for NSCLC at ESMO 2022
Alphamab Oncology (stock code: 9966.HK) announced that the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line（1L）treatment for NSCLC were poster presented at 2022 ESMO annual conference.
PR Newswire
Updated Data Presented for KN026 comboKN046 in 1st Line HER2-Positive Gastric/Gastroesophageal Junction Cancer (GC/GEJ)
Alphamab Oncology (stock code: 9966.HK) announced that data from the phase II clinical study of the chemo-free regimen of KN026 in combination with KN046 (KN026-203) were presented as a Poster at the ESMO Congress 2022 (ESMO 2022).
PR Newswire
First Patient Dosed in Phase II Study of KN046 Combined with Axitinib for the First Line Treatment of Advanced Non-Small Cell Lung Cancer
Alphamab Oncology (stock code: 9966.HK) announced the first patient has been dosed in the phase II clinical study (KN046-209) of PD-L1/CTLA-4 bispecific antibody KN046 plus Axitinib for the first line treatment of advanced Non-Small Cell Lung Cancer (NSCLC).
PR Newswire
Alphamab Oncology Announced First Patient Dosed in Phase I Trial of PD-L1/OX40 Bispecific Antibody KN052
Alphamab Oncology (stock code: 9966.HK) announced that the first patient was dosed in a Phase I clinical study (KN052-CHN-001) of KN052, its proprietary PD-L1/OX40 bispecific antibody, in patients with advanced solid tumors in China.